Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in early HER2-positive breast cancer
NCT03726879Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive breast cancer comparing Atezolizumab + ddAC-PacHP with Placebo + ddAC-PacHP (2 arms). Primary endpoints: Pathological Complete Response in PD-L1-Positive Population at 6 months and Pathological Complete Response in ITT Population at 6 months. Started Jan 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03726879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726879.